Substituted 2H-1,3-benzoxazin-4(3H)-ones

1. A compound having the formula:

wherein

R 1 is a member selected from the group consisting of C 1-6 alkyl, C 1-6 haloalkyl, C 3-5 cycloalkyl, C 3-5 cycloalkyl-alkyl, benzyl, and substituted benzyl;

R 2 is a member selected from the group consisting of H, and C 1-6 alkyl;

R 3 is a member selected from the group consisting of H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-5 cycloalkyl, C 3-5 cycloalkyl-alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, halogen, cyano and —C(O)R 3a , wherein R 3a is a member selected from the group consisting of H, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, amino, C 1-6 alkylamino and di-C 1-6 alkylamino;

R 4 is a member selected from the group consisting of H and C 1-6 alkyl;

R 5 is a member selected from the group consisting of H, C 1-6 alkyl, C 1-6 haloalkyl, benzyl, aryl, C 1-6 alkyl-N—(R 5a ) 2 ; C 1-6 alkyl-O—(R 5a ); wherein each R 5a is a member independently selected from the group consisting of H, C 1-6 alkyl, and optionally, two R 5a groups attached to nitrogen are combined with the nitrogen atom to form an azetidine, pyrrolidine, piperidine or morpholine ring;

Ar is an aromatic ring selected from the group consisting of benzene, pyridine, pyrazine and pyrimidine, each of which is optionally substituted with from 1–2 R 6 substituents,

wherein each R 6 is independently selected from the group consisting of halogen, cyano, hydroxy, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 3-5 cycloalkyl-alkoxy, amino, C 1-6 alkylamino, di-C 1-6 alkylamino, —C(═NR 6a )—N(R 6b ) 2 , —C(O)R 6a , —O(CH 2 ) m OR 6b , —(CH 2 ) m OR 6b , —O(CH 2 ) m N(R 6b ) 2 and —(CH 2 ) m N(R 6b ) 2 ,

wherein each subscript m is independently an integer of from 1 to 3, each R 6a is a member independently selected from the group consisting of H, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, amino, C 1-6 alkylamino and di-C 1-6 alkylamino, and each R 6b is a member independently selected from the group consisting of H, C 1-4 alkyl and C 1-4 alkanoyl, and optionally, two R 6b groups attached to nitrogen are combined with the nitrogen atom to form an azetidine, pyrrolidine, piperidine or morpholine ring;

L is a linking group selected from the group consisting of a bond and —NH—;

R 7 is a member selected from the group consisting of H, halogen, cyano, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy and C 1-6 haloalkyl;

and pharmaceutically acceptable salts thereof.

2. A compound of claim 1 , having the formula:

wherein the subscript n is an integer of from 0 to 2.

3. A compound of claim 1 , having the formula:

wherein the subscript n is an integer of from 0 to 2.

4. A compound of claim 1 , having the formula:

wherein the subscript n is an integer of from 0 to 2.

5. A compound of claim 1 , having the formula:

wherein the subscript n is an integer of from 0 to 2.

6. A compound of claim 2 , wherein n is 0 or 1; R 1 is C 1-4 alkyl, C 3-5 cycloalkyl, C 3-5 cycloalkyl-alkyl, or halosubstituted benzyl; R 2 is H; R 3 is H, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-5 cycloalkyl, C 3-5 cycloalkyl-alkyl, C 1-4 haloalkyl, cyano or —C(O)R 3a ; R 4 is H or C 1-4 alkyl; R 5 is H or C 1-4 alkyl, C 1-4 haloalkyl, —CN, —C≡CH or —CONH 2 ; R 6 , when present is selected from the group consisting of halogen, C 1-4 alkyl, C 1-4 alkoxy, C 3-5 cycloalkyl-alkoxy, —O(CH 2 ) m OR 6b and —O(CH 2 ) m N(R 6b ) 2 wherein the subscript m is 1 or 2 and each R 6b is independently selected from the group consisting of H, C 1-4 alkyl and C 1-4 alkanoyl; R 7 is H, C 1-4 alkyl or halogen.

7. A compound of claim 6 , wherein R 1 is C 1-4 alkyl; R 4 is H or CH 3 ; R 5 is H or CH 3 ; R 6 , when present is selected from the group consisting of halogen, C 1-4 alkyl, C 1-4 alkoxy; R 7 is halogen or C 1-4 alkyl.

8. A compound of claim 7 , wherein R 1 is methyl; R 4 is H; R 5 is H or CH 3 ; R 7 is chloro, and is attached at the 5-position of the thienyl ring; n is 0 or 1, and R 6 when present is selected from the group consisting of halogen, C 1-4 alkyl, —OCH 2 CH 2 OH, —OCH 2 CH 2 OCH 3 , —OCH 2 OCH 3 , —OCH 2 CH 2 OC(O)CH 3 and —O(CH 2 ) 2 N(CH 3 ) 2 .

9. A compound of claim 1 , having the formula:

10. A compound of claim 1 , selected from the group consisting of:

11. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the formula:

or a pharmaceutically acceptable salt thereof, wherein

R 1 is a member selected from the group consisting of C 1-6 alkyl, C 1-6 haloalkyl, C 3-5 cycloalkyl, C 3-5 cycloalkyl-alkyl, benzyl, and substituted benzyl;

R 2 is a member selected from the group consisting of H, and C 1-6 alkyl;

R 3 is a member selected from the group consisting of H, C 1-6 alky C 2-6 alkenyl, C 2-6 alkynyl, C 3-5 cycloalkyl, C 3-5 cycloalkyl-alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, halogen, cyano and —C(O)R 3a , wherein R 3a is a member selected from the group consisting of H, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, amino, C 1-6 alkylamino and di-C 1-6 alkylamino;

R 4 is a member selected from the group consisting of H and C 1-6 alkyl;

R 5 is a member selected from the group consisting of H, C 1-6 alkyl, C 1-6 haloalkyl, benzyl, aryl, C 1-6 alkyl-N—(R 5a ) 2 ; C 1-6 alkyl-O—(R 5a ); wherein each R 5a is a member independently selected from the group consisting of H, C 1-6 alkyl, and optionally, two R 5a groups attached to nitrogen are combined with the nitrogen atom to form an azetidine, pyrrolidine, piperidine or morpholine ring;

Ar is an aromatic ring selected from the group consisting of benzene, pyridine, pyrazine and pyrimidine, each of which is optionally substituted with from 1–2 R 6 substituents,

wherein each R 6 is independently selected from the group consisting of halogen, cyano, hydroxy, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 3-5 cycloalkyl-alkoxy, amino, C 1-6 alkylamino, di-C 1-6 alkylamino, —C(═NR 6a )—N(R 6b ) 2 , —C(O)R 6a , —O(CH 2 ) m OR 6b , —(CH 2 ) m OR 6b , —O(CH 2 ) m N(R 6b ) 2 and —(CH 2 ) m N(R 6b ) 2 ,

wherein each subscript m is independently an integer of from 1 to 3, each R 6a is a member independently selected from the group consisting of H, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, amino, C 1-6 alkylamino and di-C 1-6 alkylamino, and each R 6b is a member independently selected from the group consisting of H, C 1-4 alkyl and C 1-4 alkanoyl, and optionally, two R 6b groups attached to nitrogen are combined with the nitrogen atom to form an azetidine, pyrrolidine, piperidine or morpholine ring;

L is a linking group selected from the group consisting of a bond and —NH—;

R 7 is a member selected from the group consisting of H, halogen, cyano, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy and C 1-6 haloalkyl;

and pharmaceutically acceptable salts thereof.

12. A pharmaceutical composition of claim 11 , wherein said compound has a formula selected from the group consisting of:

wherein subscript n is an integer from 0 to 2.

13. A pharmaceutical composition as in claim 12 , wherein subscript n is 0 or 1; R 1 is C 1-4 alkyl, C 3-5 cycloalkyl, C 3-5 cycloalkyl-alkyl, or halosubstituted benzyl; R 2 is H; R 3 is H, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-5 cycloalkyl, C 3-5 cycloalkyl-alkyl, C 1-4 haloalkyl, cyano or —C(O)R 3a ; R 4 is H or C 1-4 alkyl; R 5 is H or C 1-4 alkyl, C 1-4 haloalkyl, —CN, —C≡CH or —CONH 2 ; R 6 , when present is selected from the group consisting of halogen, C 1-4 alkyl, C 1-4 alkoxy, C 3-5 cycloalkyl-alkoxy, —O(CH 2 ) m OR 6b and —O(CH 2 ) m N(R 6b ) 2 wherein the subscript m is 1 or 2 and each R 6b is independently selected from the group consisting of H, C 1-4 alkyl and C 1-4 alkanoyl; R 7 is H, C 1-4 alkyl or halogen.

14. A pharmaceutical composition of claim 13 , wherein R 1 is C 1-4 alkyl; R 4 is H or CH 3 ; R 5 is H or CH 3 ; R 6 , when present is selected from the group consisting of halogen, C 1-4 alkyl, C 1-4 alkoxy; R 7 is halogen or C 1-4 alkyl.

15. A pharmaceutical composition of claim 14 , wherein R 1 is methyl; R 4 is H; R 5 is H or CH 3 ; R 7 is chloro, and is attached at the 5-position of the thienyl ring; n is 0 or 1, and R 6 when present is selected from the group consisting of halogen, C 1-4 alkyl, —OCH 2 CH 2 OH, —OCH 2 CH 2 OCH 3 , —OCH 2 OCH 3 , —OCH 2 CH 2 OC(O)CH 3 and —O(CH 2 ) 2 N(CH 3 ) 2 .

16. A pharmaceutical composition of claim 11 , wherein said compound is selected from the group consisting of:

17. A method of treating a thrombosis by inhibiting a platelet ADP receptor in a subject comprising administering to a subject in need thereof, a therapeutically effective amount of a compound having the formula:

wherein

R 1 is a member selected from the group consisting of C 1-6 alkyl, C 1-6 haloalkyl, C 3-5 cycloalkyl, C 3-5 cycloalkyl-alkyl, benzyl, and substituted benzyl;

R 2 is a member selected from the group consisting of H, and C 1-6 alkyl;

R 3 is a member selected from the group consisting of H, C 1-6 alky C 2-6 alkenyl, C 2-6 alkynyl, C 3-5 cycloalkyl, C 3-5 cycloalkyl-alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, halogen, cyano and —C(O)R 3a , wherein R 3a is a member selected from the group consisting of H, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, amino, C 1-6 alkylamino and di-C 1-6 alkylamino;

R 4 is a member selected from the group consisting of H and C 1-6 alkyl;

R 5 is a member selected from the group consisting of H, C 1-6 alkyl, C 1-6 haloalkyl, benzyl, aryl, C 1-6 alkyl-N—(R 5a ) 2 ; C 1-6 alkyl-O—(R 5a ); wherein each R 5a is a member independently selected from the group consisting of H, C 1-6 alkyl, and optionally, two R 5a groups attached to nitrogen are combined with the nitrogen atom to form an azetidine, pyrrolidine, piperidine or morpholine ring;

Ar is an aromatic ring selected from the group consisting of benzene, pyridine, pyrazine and pyrimidine, each of which is optionally substituted with from 1–2 R 6 substituents,

wherein each R 6 is independently selected from the group consisting of halogen, cyano, hydroxy, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 3-5 cycloalkyl-alkoxy, amino, C 1-6 alkylamino, di-C 1-6 alkylamino, —C(═NR 6a )—N(R 6b ) 2 , —C(O)R 6a , —O(CH 2 ) m OR 6b , —(CH 2 ) m OR 6b , —O(CH 2 ) m N(R 6b ) 2 and —(CH 2 ) m N(R 6b ) 2 ,

wherein each subscript m is independently an integer of from 1 to 3, each R 6a is a member independently selected from the group consisting of H, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, amino, C 1-6 alkylamino and di-C 1-6 alkylamino, and each R 6b is a member independently selected from the group consisting of H, C 1-4 alkyl and C 1-4 alkanoyl, and optionally, two R 6b groups attached to nitrogen are combined with the nitrogen atom to form an azetidine, pyrrolidine, piperidine or morpholine ring;

L is a linking group selected from the group consisting of a bond and —NH—; and

R 7 is a member selected from the group consisting of H, halogen, cyano, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy and C 1-6 haloalkyl; or a pharmaceutically acceptable salt thereof.

18. A method in accordance with claim 17 , wherein said compound is administered in combination with a second therapeutic agent selected from the group consisting of antiplatelet compounds, anticoagulants, fibrinolytics, anti-inflammatory compounds, cholesterol-lowering agents, blood pressure-lowering agents and serotonin blockers.

19. A method in accordance with claim 18 , wherein said second therapeutic agent is an antiplatelet compound selected from the group consisting of GPIIB-IIIa antagonists, aspirin, phosphodiesterase III inhibitors and thromboxane A2 receptor antagonists.

20. A method in accordance with claim 18 , wherein said second therapeutic agent is an anticoagulant selected from the group consisting of thrombin inhibitors, coumadin, heparin and enoxaparin sodium injection.

21. A method in accordance with claim 18 , wherein said second therapeutic agent is an anti-inflammatory compound selected from the group consisting of non-steroidal anti-inflammatory agents, cyclooxygenase-2 inhibitors and rheumatoid arthritis agents.

22. A method in accordance with claim 18 , wherein said compound is administered orally or intravenously.

23. A method in accordance with claim 17 , wherein said compound has a formula selected from the group consisting of:

wherein subscript n is from 0 to 2.

24. A method in accordance with claim 23 , wherein n is 0 or 1; R 1 is C 1-4 alkyl, C 3-5 cycloalkyl, C 3-5 cycloalkyl-alkyl, or halosubstituted benzyl; R 2 is H; R 3 is H, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-5 cycloalkyl, C 3-5 cycloalkyl-alkyl, C 1-4 haloalkyl, cyano or —C(O)R 3a ; R 4 is H or C 1-4 alkyl; R 5 is H or C 1-4 alkyl, C 1-4 haloalkyl, —CN, —C≡CH or —CONH 2 ; R 6 , when present is selected from the group consisting of halogen, C 1-4 alkyl, C 1-4 alkoxy, C 3-5 cycloalkyl-alkoxy, —O(CH 2 ) m OR 6b and —O(CH 2 ) m N(R 6b ) 2 wherein the subscript m is 1 or 2 and each R 6b is independently selected from the group consisting of H, C 1-4 alkyl and C 1-4 alkanoyl; R 7 is H, C 1-4 alkyl or halogen.

25. A method in accordance with claim 24 , wherein R 1 is C 1-4 alkyl; R 4 is H or CH 3 ; R 5 is H or CH 3 ; R 6 , when present is selected from the group consisting of halogen, C 1-4 alkyl, C 1-4 alkoxy; R 7 is halogen or C 1-4 alkyl.

26. A method in accordance with claim 25 , wherein R 1 is methyl; R 4 is H; R 5 is H or CH 3 ; R 7 is chloro, and is attached at the 5-position of the thienyl ring; n is 0 or 1, and R 6 when present is selected from the group consisting of halogen, C 1-4 alkyl, —OCH 2 CH 2 OH, —OCH 2 CH 2 OCH 3 , —OCH 2 OCH 3 , —OCH 2 CH 2 OC(O)CH 3 and —O(CH 2 ) 2 N(CH 3 ) 2 .

27. A method in accordance with claim 17 , wherein said compound is selected from the group consisting of: